Physician profile
Edwin Posadas
NPI 1720140270
$128,750.49
in general payments reported to CMS, 2019-2025
19 companies · $16K in 2025
The $16K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $8,823 · 2021: $3,100 · 2022: $26K · 2023: $35K · 2024: $24K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Consulting Fee: $25K · Travel and Lodging: $10K · Food and Beverage: $1,335 · Education: $7.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,374.00 |
| Consulting Fee | $24,959.75 |
| Travel and Lodging | $10,171.42 |
| Food and Beverage | $1,335.39 |
| Education | $7.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $97,932.23 | 2019-2025 | |
| Genzyme Corporation | $8,553.28 | 2019-2023 | |
| Myovant Sciences INC. | $6,263.90 | 2021-2022 | |
| Janssen Biotech, INC. | $4,562.35 | 2019-2023 | |
| Advanced Accelerator Applications | $4,516.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $2,588.07 | 2020-2023 | |
| Pfizer INC. | $2,191.39 | 2022-2025 | |
| Seagen INC. | $1,054.88 | 2020 | |
| Janssen Scientific Affairs, LLC | $825.00 | 2023 | |
| Bayer Healthcare LLC | $86.65 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $79.36 | 2023 | |
| Dendreon Pharmaceuticals LLC | $68.45 | 2025 | Provenge |
| Takeda Pharmaceuticals U.S.A., INC. | $28.88 | 2024 | Fruzaqla |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Posadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.